Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the
development of revolutionary bone graft material and coatings for
medical applications, is pleased to announce the addition of Jimmy
Bornheimer, Vice President of Finance, and Stephen Smith, Vice President
of Regulatory and Quality Assurance. Both Mr. Bornheimer and Mr. Smith
bring vast experience in their fields and fill new positions within
Bacterin’s management team.
“Mr. Bornheimer and Mr. Smith bring extensive experience in their areas
of expertise, and will fill key roles as Bacterin grows,” said Dan
Goldberger, Bacterin President and CEO.
Mr. Bornheimer has over 25 years of experience in various senior level
financial and business development roles with companies in the medical
device industry. Prior to his appointment at Bacterin, he was Chief
Financial Officer of Sound Surgical Technologies LLC which was acquired
by Solta Medical Inc. in February of last year. Prior to that, he held a
number of financial positions during his fifteen years with Pfizer Inc.
in its Hospital Product Group Division. As Vice President of Finance,
Mr. Bornheimer will report to John Gandolfo, the Company's Chief
Financial Officer, and will have responsibility over the day-to-day
financial activities for Bacterin as well as internal and SEC reporting.
Mr. Smith brings over 25 years of experience in senior regulatory and
quality assurance positions in the medical device industry, including
experience in tissue banking as well. His most recent position was Vice
President of Regulatory Affairs and Quality Assurance for Sound Surgical
Technologies LLC/Solta Medical. Prior to this position, Mr. Smith worked
for AlloSource and Valleylab (Covidien). He has extensive knowledge
pertaining to ISO 13485, FDA, and AATB regulatory requirements,
guidelines, and standards. As Vice President of Regulatory and Quality
Assurance for Bacterin, he will oversee Bacterin’s Regulatory and
Quality department and Bacterin’s Quality System.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops,
manufactures, and markets biologics products to domestic and
international markets. These products are used in a variety of
applications including enhancing fusion in spine surgery, relief of back
pain, promotion of bone growth in foot and ankle surgery, promotion of
cranial healing following neurosurgery and subchondral repair in knee
and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses
coatings for various medical device applications. For further
information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that are subject to significant risks and
uncertainties. Forward-looking statements include statements that are
predictive in nature, that depend upon or refer to future events or
conditions, or that include words such as "continue," "efforts,"
"expects," "anticipates," "intends," "plans," "believes," "estimates,"
"projects," "forecasts," "strategy," "will," "goal," "target,"
"prospects," "potential," "optimistic," "confident," "likely,"
"probable" or similar expressions or the negative thereof. Statements of
historical fact also may be deemed to be forward-looking statements. We
caution that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a
variety of important factors, including, among others: the Company's
ability to meet its existing and anticipated contractual obligations,
including financial covenant and other obligations contained in the
Company’s secured lending facility; the Company’s ability to manage cash
flow and achieve profitability; the Company's ability to develop,
market, sell and distribute desirable applications, products and
services and to protect its intellectual property; the ability of the
Company's sales force to achieve expected results; the ability of the
Company's customers to pay and the timeliness of such payments; the
Company's ability to obtain financing as and when needed; changes in
consumer demands and preferences; the Company's ability to attract and
retain management and employees with appropriate skills and expertise;
the Company’s ability to successfully conclude government
investigations; the Company’s ability to remain listed on the NYSE MKT;
the impact of changes in market, legal and regulatory conditions and in
the applicable business environment, including actions of competitors;
and other factors. Additional risk factors are listed in the Company's
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the
heading "Risk Factors." The Company undertakes no obligation to release
publicly any revisions to any forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events, except as required by law.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140408006016r1&sid=ntxv4&distro=nx)
Copyright Business Wire 2014